Cargando…
Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2(+) diffuse large B-cell lymphomas
Although oncogenicity of the stem cell regulator SOX9 has been implicated in many solid tumors, its role in lymphomagenesis remains largely unknown. In this study, SOX9 was overexpressed preferentially in a subset of diffuse large B-cell lymphomas (DLBCLs) that harbor IGH-BCL2 translocations. SOX9 p...
Autores principales: | Shen, Yajie, Zhou, Jingqi, Nie, Kui, Cheng, Shuhua, Chen, Zhengming, Wang, Wenhan, Wei, Weiqing, Jiang, Daiji, Peng, Zijing, Ren, Yizhuo, Zhang, Yirong, Fan, Qiuju, Richards, Kristy L., Qi, Yitao, Cheng, Jinke, Tam, Wayne, Ma, Jiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740888/ https://www.ncbi.nlm.nih.gov/pubmed/34624089 http://dx.doi.org/10.1182/blood.2021012327 |
Ejemplares similares
-
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023) -
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022) -
The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia
por: Laidou, Stamatia, et al.
Publicado: (2022) -
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021) -
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)